Pfizer has a VEGF bispecific strategy. And it’s very different than Summit’snews2025-09-12T12:44:58+00:00September 12th, 2025|Endpoints News|
The UK is falling behind on life science investments, trade group warns news2025-09-11T14:17:12+00:00September 11th, 2025|Endpoints News|
A conversation with Lasker Award winner Michael Welsh on life-saving cystic fibrosis drugsnews2025-09-11T13:18:56+00:00September 11th, 2025|Endpoints News|
Revolution’s lead RAS blocker heads into Phase 3 in frontline pancreatic cancer after early datanews2025-09-11T11:01:24+00:00September 11th, 2025|Endpoints News|
Patient dies in Capsida study for rare brain disordernews2025-09-11T07:20:19+00:00September 11th, 2025|Endpoints News|
Merck cancels plans for $1.3B London labnews2025-09-10T19:43:00+00:00September 10th, 2025|Endpoints News|
Avidity shares functional data ahead of plans to submit Duchenne exon skipping drug by year’s endnews2025-09-10T14:59:18+00:00September 10th, 2025|Endpoints News|
Trump directs more FDA enforcement of pharma adsnews2025-09-09T22:57:25+00:00September 9th, 2025|Endpoints News|
Lundbeck to transfer commercial drugs to three partners in 27 marketsnews2025-09-09T18:08:18+00:00September 9th, 2025|Endpoints News|
Ideaya touts trio of cancer drugs as it eyes spot in precision oncology marketnews2025-09-09T15:15:45+00:00September 9th, 2025|Endpoints News|
